Endocyte Ovarian Cancer Duo Is Nearing European Market
Endocyte Inc.'s stock jumped 25 percent Tuesday on news that it would be applying for marketing authorization from the European Medicines Agency for two of its products: ovarian cancer candidate EC145 and a companion imaging diagnostic EC20 for patient selection.
To continue reading subscribe now to BioWorld Today
Learn More about BioWorld Today
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.